Skip to content

Immunovant, Inc. IMVT Prepaid expenses

Prepaid expenses at other companies

IQVIA logo
IQVIAIQV
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseCurrent.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s prepaid expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s prepaid expenses?
Immunovant, Inc. (IMVT) reported prepaid expenses of $42.76M in Q1 2026.
How has Immunovant, Inc.'s prepaid expenses changed year-over-year?
Immunovant, Inc.'s prepaid expenses decreased by 16.4% year-over-year, from $51.18M to $42.76M.
What is the long-term trend for Immunovant, Inc.'s prepaid expenses?
Over 5 years (2021 to 2026), Immunovant, Inc.'s prepaid expenses has grown at a 40.8% compound annual growth rate (CAGR), from $7.72M to $42.76M.